www.ijbcp.com International Journal of Basic & Clinical Pharmacology | August 2019 | Vol 8 | Issue 8 Page 1906 IJBCP International Journal of Basic & Clinical Pharmacology Print ISSN: 2319-2003 | Online ISSN: 2279-0780 Original Research Article Evaluation of antidiabetic efficacy of Murraya koenigii on Streptozotocin induced diabetes in experimental rats Rajesh Kumar Suman 1 *, Ipseeta Ray Mohanty 2 , Manjusha K. Borde 3 , Y. A. Deshmukh 2 , Anurag Pathak 1 , Arun Kumar Adhikari 1 , H. K. Singh 1 INTRODUCTION Many herbal agents have been described for the treatment of diabetic mellitus in ancient literature. 1,2 The global prevalence of type 2 diabetes mellitus (T2DM) is on the rise and at the current rate the estimates for the year 2000 through 2030 show that this global epidemic will have an increase from 171-366 million patients. 3 Curry leaf extract possess the property to decrease blood cholesterol and blood glucose level in diabetic ob/ob mice. Mice were given daily injection of 80 mg/kg of leaves extract intraperitonially for 10 consecutive days. Blood glucose was found to be reduced after the administration of extract. This study suggests that Murraya koenigii may be proved to be clinically important in improving the management of type 2 diabetes. 4,5 ABSTRACT Background: The medicinal plant Murraya koenigii shown to have a wide variety of pharmacological activities (hypoglycemic and hypolipidemic). Objective of this study is the present study was designed to evaluate Antidiabetic and Hypolipidemic property of Murraya koenigii in experimentally induced diabetes in rats. Methods: Experimental diabetes was produced with single dose of Streptozotocin (STZ): 45 mg/kg IP. The rats were randomly allocated in various groups for 37 days. After the confirmation of diabetes on 7 th day (>200 mg/dl), hydroalcoholic extract of Murraya koenigii (500 mg/kg) was administered orally to experimental rats from day 7 th day and continued for 37 days thereafter. Various antidiabetic (Glucose, HbA1C), metabolic (Lipid profile), safety (pancreatic lipase, Creatinine, SGPT, Histopathology of Liver and Kidney) were evaluated in various group. Results: Efficacy of Murraya koenigii was observed on various parameter of diabetes. Administration of STZ resulted in a significant decrease in diabetic changes (increase in blood glucose, HbA1C), altered lipid profile (p<0.01) in the Control group rats as compared to sham group. Murraya koenigii treatment demonstrated significant antidiabetic indicated by restoration of blood glucose, HbA1C level (p<0.01) compared to Control group. In addition, Murraya koenigii also documented hypolipidemic property of test drug. As per biochemical assessment of Pancreatic lipase, Serum creatinine, SGPT and Histopathological report, the test drug reduce the pancreatic, liver and renal marker and also showed safe to pancreas, Liver and kidney. The histopathological assessment of the liver and kidney confirmed the biochemical findings. Conclusions: The study concluded that the Murraya koenigii possess antidiabetic efficacy Keywords: Blood glucose, Diabetes, Experimental rats, Medicinal plant, Murraya koenigii, Streptozotocin DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20193200 1 Department of Pharmacology, Hind Institute of Medical Sciences, Mau, Lucknow, India 2 Department of Pharmacology, MGM Medical College, Navi Mumbai, Maharashtra, India 3 Department of Pharmacology, Sinhgad Dental College, Pune, Maharashtra, India Received: 13 June 2019 Revised: 29 June 2019 Accepted: 06 July 2019 *Correspondence to: Dr. Rajesh Kumar Suman, Email: rajeshsuman2043@ gmail.com Copyright: © the author(s), publisher and licensee Medip Academy. This is an open- access article distributed under the terms of the Creative Commons Attribution Non- Commercial License, which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.